I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Efficacy of crizotinib retreatment after crizotinib-related..:
Woo Kyung Ryu
;
Hyungkeun Cha
;
Mi Hwa Park
...
https://www.frontiersin.org/articles/10.3389/fonc.2022.900966/full. , 2022
Link:
https://doi.org/10.3389/fonc.2022.900966
RT Journal T1
Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:b73e9e7bdfab4634bcbd5c44c81f3286&Exemplar=1&LAN=DE A1 Woo Kyung Ryu A1 Hyungkeun Cha A1 Mi Hwa Park A1 Jung Soo Kim A1 Jeong-Seok Choi A1 Lucia Kim A1 Kyung-Hee Lee A1 Hae-Seong Nam PB Frontiers Media S.A. YR 2022 K1 interstitial lung disease (ILD) K1 ALK (anaplastic lymphoma kinase) K1 ROS1 K1 tyrosine kinase inhibitor (TKI) K1 crizotinib K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://www.frontiersin.org/articles/10.3389/fonc.2022.900966/full LK http://dx.doi.org/https://doi.org/10.3389/fonc.2022.900966 DO https://doi.org/10.3389/fonc.2022.900966 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)